Last reviewed · How we verify
GLP-1 analogs
GLP-1 analogs mimic the action of the hormone glucagon-like peptide-1 to regulate blood sugar levels.
GLP-1 analogs mimic the action of the hormone glucagon-like peptide-1 to regulate blood sugar levels. Used for Type 2 diabetes, Weight management.
At a glance
| Generic name | GLP-1 analogs |
|---|---|
| Also known as | incretin-based drugs, exenatide, liraglutide |
| Sponsor | Canadian Network for Observational Drug Effect Studies, CNODES |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
GLP-1 analogs bind to and activate the GLP-1 receptor, which increases insulin secretion and decreases glucagon secretion. This leads to improved glycemic control and weight loss in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
- Weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
Key clinical trials
- Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery (NA)
- DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies (PHASE4)
- Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy (NA)
- Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
- Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition (PHASE3)
- The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure (PHASE4)
- Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes (PHASE3)
- GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-1 analogs CI brief — competitive landscape report
- GLP-1 analogs updates RSS · CI watch RSS
- Canadian Network for Observational Drug Effect Studies, CNODES portfolio CI